EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Euglycemic SGLT2 Inhibitor–Associated Ketoacidosis in a Nondiabetic Patient: A Case Report

Carmelo Zinnato iD, Teresa Roatta iD, Giacomo Berta iD, Roberto Penso iD, Vincenzo Russotto iD

Case Reports in Critical Care · 2026-01 · 2026 (1)

DOI: 10.1155/crcc/3970190 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Critical Care, online erschienen am 25.10.2026. Verfasst von Carmelo Zinnato und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesia and Critical Care University Hospital San Luigi Gonzaga University of Turin Turin Italy unito.it. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We present the case of a 62‐year‐old nondiabetic woman receiving dapagliflozin for dilated cardiomyopathy presenting to the emergency department with severe hypoxemic respiratory failure because of suspected cardiogenic pulmonary edema. Despite treatment, she remained symptomatic and required intubation and intensive care admission. After intubation, high‐anion‐gap metabolic acidosis was unmasked. After exclusion of other common causes, SGLT2 inhibitor–associated ketoacidosis due to dapagliflozin was suspected. Marked ketonuria confirmed the diagnosis despite the absence of hyperglycemia. Dapagliflozin was discontinued, and intravenous insulin, glucose infusion, and early enteral nutrition were initiated. Metabolic acidosis resolved completely within 24 h. The patient was successfully extubated and discharged from the intensive care unit 48 h later. SGLT2 inhibitor–associated ketoacidosis should be considered in patients receiving sodium‐glucose cotransporter‐2 inhibitors who develop otherwise unexplained high‐anion‐gap metabolic acidosis, irrespective of diabetic status or blood glucose concentration. Fasting and acute illness are relevant precipitating factors; prompt drug withdrawal, carbohydrate administration, insulin therapy, and nutritional support can lead to rapid resolution.

Schlagwörter

Stichwörter der Autor:innen

ICUSGLT2 inhibitor–associated ketoacidosiseuglycemic ketoacidosissodium-glucose cotransporter-2 inhibitors

Autor:innen und Institutionen

  • Department of Anesthesia and Critical Care University Hospital San Luigi Gonzaga University of Turin Turin Italy unito.it.
  • Department of Surgical Sciences University of Turin Turin Italy unito.it.
  • Department of Oncology University of Turin Turin Italy unito.it.

ORCID-Profile: Carmelo Zinnato, Teresa Roatta, Giacomo Berta, Roberto Penso, Vincenzo Russotto

Zitieren

APA

Zinnato, C., Roatta, T., Berta, G., Penso, R., & Russotto, V. (2026). Euglycemic SGLT2 Inhibitor–Associated Ketoacidosis in a Nondiabetic Patient: A Case Report. Case Reports in Critical Care, 2026(1). https://doi.org/10.1155/crcc/3970190

Vancouver

Zinnato C, Roatta T, Berta G, Penso R, Russotto V. Euglycemic SGLT2 Inhibitor–Associated Ketoacidosis in a Nondiabetic Patient: A Case Report. Case Reports in Critical Care. 2026;2026(1). doi:10.1155/crcc/3970190

BibTeX
@article{Zinnato2026,
  author = {Zinnato, Carmelo and Roatta, Teresa and Berta, Giacomo and Penso, Roberto and Russotto, Vincenzo},
  title = {Euglycemic SGLT2 Inhibitor–Associated Ketoacidosis in a Nondiabetic Patient: A Case Report},
  journal = {Case Reports in Critical Care},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crcc/3970190}
}
Kostenlos starten →